Professor Vassilis Gorgoulis and colleagues published in Molecular Cancer (IF 27,7) (https://link.springer.com/article/10.1186/s12943-024-02061-4) a work that uncovers how loss of the tumour suppressor LKB1/STK11 provides a pivotal metabolic vulnerability window for therapeutic exploitation as a precision medical treatment.
Loss of the tumour suppressor LKB1/STK11 uncovers a leptin-mediated sensitivity mechanism to mitochondrial uncouplers for targeted cancer therapy
Angelopoulou A, Theocharous G, Valakos D, Polyzou A, Magkouta S, Myrianthopoulos V, Havaki S, Fiorillo M, Tremi I, Vachlas K, Nisotakis T, Thanos DF, Pantazaki A, Kletsas D, Bartek J, Petty R, Thanos D, McCrimmon RJ, Papaspyropoulos A, Gorgoulis VG.
Mol Cancer. 2024 Jul 25;23(1):147. doi: 10.1186/s12943-024-02061-4.